B7x in cancer immunity and immunotherapy

Area of Science:

• Immunology
• Oncology
• Cancer Research

Background:

• B7x (B7-H4) is a co-inhibitory molecule highly expressed in cold tumors, associated with poor patient outcomes.
• Aberrant B7x expression suppresses anti-tumor immunity by inhibiting T cell proliferation and effector functions.
• B7x acts as an alternative immune checkpoint, contributing to resistance against existing immunotherapies like PD-1/PD-L1 blockade.

Purpose of the Study:

• To investigate the role of B7x in cancer progression and immune evasion.
• To evaluate B7x as a potential biomarker for predicting treatment response.
• To explore anti-B7x therapies as a novel approach for overcoming immunotherapy resistance.

Main Methods:

• Analysis of B7x expression in tumor cells and antigen-presenting cells (APCs).
• Assessment of B7x's impact on CD4+ and CD8+ T cell function and regulatory T cell (Treg) generation.
• Evaluation of serum B7x levels as a biomarker.
• Investigation of anti-B7x antibodies and bispecific antibodies targeting B7x in preclinical models.

Main Results:

• B7x overexpression is linked to suppressed T cell activity and increased immunosuppressive cells in the tumor microenvironment (TME).
• Serum B7x levels show potential as a biomarker for treatment response.
• Anti-B7x strategies can reinvigorate exhausted T cells and overcome resistance to PD-1/PD-L1/CTLA-4 therapies.
• Bispecific antibodies targeting B7x represent an advanced therapeutic strategy.

Conclusions:

• B7x is a critical mediator of immune suppression in cold tumors and a target for novel cancer immunotherapies.
• Targeting B7x, particularly in combination with other immune checkpoint inhibitors, holds promise for improving outcomes in resistant cancers.
• Further development of anti-B7x therapies, including bispecific antibodies, is warranted to enhance anti-tumor immunity.